Dopaminergic function and progression of Parkinson's disease: PET findings

Parkinsonism and Related Disorders

Volumn 15, Issue SUPPL. 4, 2009, Pages

  Biju, G ^a   de la Fuente Fernandez R ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Dopamine; Parkinson's disease; Positron emission tomography; Progression

Indexed keywords

ARTICLE; DISEASE COURSE; DOPAMINERGIC SYSTEM; HUMAN; MOTOR DYSFUNCTION; NERVE DEGENERATION; NERVE ENDING; NEUROIMAGING; NIGRONEOSTRIATAL SYSTEM; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRESYNAPTIC POTENTIAL; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ANIMAL; CORPUS STRIATUM; PATHOLOGY; PHYSIOLOGY; PROCEDURES; SCINTISCANNING; SUBSTANTIA NIGRA; SYNAPTOSOME;

DOPAMINE;

ANIMALS; CORPUS STRIATUM; DISEASE PROGRESSION; DOPAMINE; HUMANS; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; PRESYNAPTIC TERMINALS; SUBSTANTIA NIGRA;

EID: 72649103892     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1353-8020(09)70833-8     Document Type: Article

References (42)

1. Au W.L., Adams J.R., Troiano A.R., and Stoessl A.J. Parkinson's disease: in vivo assessment of disease progression using positron emission tomography. Brain Res Mol Brain Res 134 (2005) 24-33
2. Bohnen N.I., and Frey K.A. Imaging of cholinergic and monoaminergic neurochemical changes in neurodegenerative disorders. Mol Imaging Biol 9 (2007) 243-257
3. Garnett E.S., Firnau G., and Nahmias C. Dopamine visualized in the basal ganglia of living man. Nature 305 (1983) 137-138
4. Gjedde A., Reith J., Dyve S., Léger G., Guttman M., Diksic M., et al. Dopa decarboxylase activity of the living human brain. Proc Natl Acad Sci USA 88 (1991) 2721-2725
5. Volkow N.D., Ding Y.S., Fowler J.S., Wang G.J., Logan J., Gatley S.J., et al. A new PET ligand for the dopamine transporter: studies in the human brain. J Nucl Med 36 (1995) 2162-2168
6. Frey K.A., Koeppe R.A., Kilbourn M.R., Vander Borght T.M., Albin R.L., Gilman S., et al. Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging. Ann Neurol 40 (1996) 873-884
7. 18F]fluorodopa studies correlate with dopamine cell counts and levels. Ann Neurol 34 (1993) 324-330
8. Lee C.S., Samii A., Sossi V., Ruth T.J., Schulzer M., Holden J.E., et al. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann Neurol 47 (2000) 493-503
9. de la Fuente-Fernández R., Furtado S., Guttman M., Furukawa Y., Lee C.S., Calne D.B., et al. VMAT2 binding is elevated in dopa-responsive dystonia: visualizing empty vesicles by PET. Synapse 49 (2003) 20-28
10. de la Fuente-Fernández R., Sossi V., McCormick S., Schulzer M., Ruth T.J., and Stoessl A.J. Visualizing vesicular dopamine dynamics in Parkinson's disease. Synapse 63 (2009) 713-716
11. 11C]raclopride in the human brain. Synapse 16 (1994) 255-262
12. Laruelle M. Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J Cereb Blood Flow Metab 20 (2000) 423-451
13. de la Fuente-Fernández R., Lu J.Q., Sossi V., Jivan S., Schulzer M., Holden J.E., et al. Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover. Ann Neurol 49 (2001) 298-303
14. Bernheimer H., Birkmayer W., Hornykiewicz O., Jellinger K., and Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 20 (1973) 415-455
15. Kish S.J., Shannak K., and Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N Engl J Med 318 (1988) 876-880
16. Fearnley J.M., and Lees A.J. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 114 (1991) 2283-2301
17. Hornykiewicz O. Biochemical aspects of Parkinson's disease. Neurology 51 2 Suppl 2 (1998) S2-S9
18. Vingerhoets F.J., Snow B.J., Lee C.S., Schulzer M., Mak E., and Calne D.B. Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism. Ann Neurol 36 (1994) 759-764
19. 18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease. Brain 119 (1996) 585-591
20. 18F]dopa PET. J Neurol Neurosurg Psychiatry 64 (1998) 314-319
21. 18F]CFT. Ann Neurol 47 (2000) 804-808
22. 18F]fluoro-L-dopa PET study. Mov Disord 16 (2001) 608-615
23. Hilker R., Schweitzer K., Coburger S., Ghaemi M., Weisenbach S., Jacobs A.H., et al. Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity. Arch Neurol 62 (2005) 378-382
24. Lee C.S., Schulzer M., de la Fuente-Fernández R., Mak E., Kuramoto L., Sossi V., et al. Lack of regional selectivity during the progression of Parkinson disease: implications for pathogenesis. Arch Neurol 61 (2004) 1920-1925
25. Nandhagopal R., Mak E., Schulzer M., McKenzie J., McCormick S., Sossi V., et al. Progression of dopaminergic dysfunction in a LRRK2 kindred: a multitracer PET study. Neurology 71 (2008) 1790-1795
26. 18F]fluorodopa positron emission tomographic studies. Mov Disord 5 (1990) 203-213
27. Huang C., Tang C., Feigin A., Lesser M., Ma Y., Pourfar M., et al. Changes in network activity with the progression of Parkinson's disease. Brain 130 (2007) 1834-1846
28. Eckert T., Tang C., and Eidelberg D. Assessment of the progression of Parkinson's disease: a metabolic network approach. Lancet Neurol 6 (2007) 926-932
29. de la Fuente-Fernández R., Pal P.K., Vingerhoets F.J., Kishore A., Schulzer M., Mak E.K., et al. Evidence for impaired presynaptic dopamine function in parkin-sonian patients with motor fluctuations. J Neural Transm 107 (2000) 49-57
30. de la Fuente-Fernández R., Schulzer M., Mak E., Calne D.B., and Stoessl A.J. Presynaptic mechanisms of motor fluctuations in Parkinson's disease: a probabilistic model. Brain 127 (2004) 888-899
31. Sossi V., de la Fuente-Fernández R., Schulzer M., Adams J., and Stoessl J. Age-related differences in levodopa dynamics in Parkinson's: implications for motor complications. Brain 129 (2006) 1050-1058
32. Sossi V., de la Fuente-Fernández R., Schulzer M., Troiano A.R., Ruth T.J., and Stoessl A.J. Dopamine transporter relation to dopamine turnover in Parkinson's disease: a positron emission tomography study. Ann Neurol 62 (2007) 468-474
33. de la Fuente-Fernández R., Sossi V., Huang Z., Furtado S., Lu J.Q., Calne D.B., et al. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. Brain 127 (2004) 2747-2754
34. Troiano A.R., de la Fuente-Fernandez R., Sossi V., Schulzer M., Mak E., Ruth T.J., et al. PET demonstrates reduced dopamine transporter expression in PD with dyskinesias. Neurology 72 (2009) 1211-1216
35. Evans A.H., Pavese N., Lawrence A.D., Tai Y.F., Appel S., Doder M., et al. Compulsive drug use linked to sensitized ventral striatal dopamine transmission. Ann Neurol 59 (2006) 852-858
36. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 287 (2002) 1653-1661
37. Whone A.L., Watts R.L., Stoessl A.J., Davis M., Reske S., Nahmias C., et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol 54 (2003) 93-101
38. Ahlskog J.E. Slowing Parkinson's disease progression: recent dopamine agonist trials. Neurology 60 (2003) 381-389
39. Albin R.L., and Frey K.A. Initial agonist treatment of Parkinson disease: a critique. Neurology 60 (2003) 390-394
40. Schapira A.H., and Olanow C.W. Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions. JAMA 291 (2004) 358-364
41. Vander Borght T., Kilbourn M., Desmond T., Kuhl D., and Frey K. The vesicular monoamine transporter is not regulated by dopaminergic drug treatments. Eur J Pharmacol 294 (1995) 577-583
42. Wilson J.M., and Kish S.J. The vesicular monoamine transporter, in contrast to the dopamine transporter, is not altered by chronic cocaine self-administration in the rat. J Neurosci 16 (1996) 3507-3510